Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

June 3, 2025 expert reaction to observational study on low calorie diets and depressive symptoms . An observational study published in BMJ Nutrition, Prevention & Health looks at ...

Metsera, Inc. is the "new kid on the block" in the GLP-receptor agonist weight loss drug field. The recently IPO'd company has an injectable at the Phase 2b study stage, with data promised this ...

On Tuesday, Cantor Fitzgerald reiterated its Overweight rating on Metsera Inc (NASDAQ:MTSR), a $2.87 billion market cap biopharmaceutical company, following a series of virtual meetings with ...

Metsera, Inc. NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases ...

“The first quarter of 2025 was a period of focused execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera. “We remain on track to deliver on all of our ...

On Tuesday, Cantor Fitzgerald reiterated its Overweight rating on Metsera Inc (NASDAQ:MTSR), a $2.87 billion market cap biopharmaceutical company, following a series of virtual meetings with European ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

"The first quarter of 2025 was a period of focused execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera. "We remain on track to deliver on all of our committed ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...